Toxicology – Anticholinergic Syndrome

Definition

Anticholinergic syndrome is a toxidrome caused primarily by blockade of muscarinic acetylcholine receptors.

The classic presentation includes:

• Tachycardia
• Mydriasis and blurred vision
• Dry mouth and mucous membranes
• Warm, dry, flushed skin
• Decreased bowel sounds or ileus
• Urinary retention
• Agitation, delirium, and hallucinations
• Hyperthermia in more severe cases

Mechanism of Action

Antimuscarinic agents competitively inhibit acetylcholine at postsynaptic muscarinic receptors.

This reduces parasympathetic activity in the:

• Heart
• Eyes
• Sweat and salivary glands
• GI tract
• Urinary tract
• Central nervous system

Classic antimuscarinic agents do not primarily block nicotinic acetylcholine receptors.

Common Causes

Important causes include:

• First-generation antihistamines, especially diphenhydramine
• Tricyclic antidepressants
• Atropine
• Scopolamine
• Benztropine
• Oxybutynin
• Cyclobenzaprine
• Some antipsychotics
• Anticholinergic plants such as Datura and Atropa species
• Ophthalmic antimuscarinic agents

Some of these drugs have additional toxic actions. For example, severe diphenhydramine or TCA poisoning can also produce sodium-channel blockade and QRS widening.

Classic Toxidrome

A traditional mnemonic describes the syndrome as:

• “Mad as a hatter” → delirium, agitation, hallucinations
• “Hot” → hyperthermia
• “Dry as a bone” → dry skin and mucous membranes
• “Blind as a bat” → mydriasis and impaired accommodation
• “Red as a beet” → flushed skin

Not every patient develops every feature.

Vital Signs

Tachycardia is common because muscarinic blockade reduces vagal influence on the heart.

Other findings may include:

• Mild-to-moderate hyperthermia
• Hypertension from agitation
• Tachypnea
• Hypotension in severe poisoning or after seizures

HEENT

Common findings:

• Mydriasis
• Blurred vision
• Dry mouth
• Reduced secretions

Local ocular exposure can cause isolated mydriasis or anisocoria.

Skin

Typical findings are:

• Warm
• Dry
• Flushed

Reduced sweating contributes to hyperthermia.

Gastrointestinal and Genitourinary

Muscarinic blockade decreases smooth-muscle activity and secretions.

This can produce:

• Reduced bowel sounds
• Constipation
• Ileus
• Urinary retention
• Bladder distension

Neurologic Features

Central antimuscarinic toxicity may cause:

• Restlessness
• Agitation
• Confusion
• Disorientation
• Paranoia
• Visual hallucinations
• Delirium

Severe poisoning may cause:

• Seizures
• Marked hyperthermia
• Coma

Severe agitation or seizures can also produce rhabdomyolysis.

Anticholinergic vs. Sympathomimetic Toxidrome

These syndromes overlap because both can cause:

• Tachycardia
• Hypertension
• Mydriasis
• Hyperthermia
• Agitation
• Delirium

A useful distinction is the skin and GI examination:

Anticholinergic

• Dry skin
• Dry mouth
• Reduced bowel sounds
• Urinary retention

Sympathomimetic

• Diaphoresis
• Bowel sounds usually preserved or increased

Diagnosis

Diagnosis is primarily clinical, based on the toxidrome and exposure history.

Useful investigations in moderate or severe cases may include:

• ECG
• Electrolytes
• Renal function
• Glucose
• Creatine kinase when severe agitation, seizures, or hyperthermia raise concern for rhabdomyolysis
• Targeted testing for important possible coingestants

An ECG is particularly important because some anticholinergic drugs also produce cardiac sodium-channel blockade.

Management

Treatment is primarily supportive.

Important measures include:

• Airway and respiratory support when necessary
• IV fluids when clinically indicated
• External cooling for significant hyperthermia
• Cardiac monitoring in significant poisoning
• Monitoring for urinary retention
• Treatment of complications such as seizures and rhabdomyolysis

Benzodiazepines are commonly used for significant agitation and seizures.

Routine induction of vomiting and gastric lavage, as recommended in older references, are not standard modern management because their risks generally outweigh their benefits.

Activated charcoal may be considered after selected substantial recent ingestions when the airway can be safely protected.

Physostigmine

Physostigmine is a reversible acetylcholinesterase inhibitor that crosses the blood-brain barrier and can reverse both central and peripheral antimuscarinic effects.

It may be considered for severe, clinically significant antimuscarinic delirium in carefully selected patients.

It should not be treated as a routine diagnostic test for unexplained altered mental status.

Important precautions include avoiding its use when:

• TCA or another sodium-channel-blocking overdose is suspected
• The ECG shows concerning conduction abnormalities such as significant QRS widening
• The poisoning is not clearly compatible with a predominantly antimuscarinic syndrome

Because inappropriate or rapid administration can cause bradycardia, cholinergic effects, seizures, or dysrhythmias, its use requires appropriate monitoring and toxicology expertise.

Expected Course

Symptoms may develop gradually because antimuscarinic effects can slow gastrointestinal motility and delay absorption.

Many uncomplicated cases resolve within approximately a day, although severe poisoning or long-acting agents can cause symptoms lasting considerably longer.

Key Points

• Anticholinergic toxicity is primarily muscarinic receptor blockade.
• Classic findings are tachycardia + mydriasis + dry/flushed skin + decreased bowel sounds + urinary retention + delirium.
• Dry skin helps distinguish anticholinergic toxicity from the usually sweaty sympathomimetic toxidrome.
• Severe toxicity can cause hyperthermia, seizures, rhabdomyolysis, and coma.
• ECG assessment is important because some causative drugs have additional cardiotoxic effects.
• Benzodiazepines and supportive care are central to treatment.
• Physostigmine can rapidly reverse severe antimuscarinic delirium in appropriately selected patients, but it requires careful screening for contraindications.
• Older recommendations for routine ipecac or gastric lavage are obsolete.

Ophthalmology – Unexplained High-Anion-Gap Metabolic Acidosis

What the Disorder Represents

High-anion-gap metabolic acidosis (HAGMA) is a metabolic acid-base disturbance caused by accumulation of acids whose accompanying anions are not routinely measured on the standard electrolyte panel.

The basic calculation is:

Anion gap = Na⁺ − (Cl⁻ + HCO₃⁻)

The key clinical question is not simply whether bicarbonate is low, but:

Why has an unmeasured acid accumulated?

This can represent a life-threatening emergency from:

• Lactic acidosis
• Ketoacidosis
• Renal failure
• Toxic alcohol poisoning
• Salicylate poisoning
• Other severe toxic or metabolic disorders

Important Modern Correction: Metabolic Acidosis Is Not Defined by Bicarbonate Alone

A serum bicarbonate below 24 mEq/L does not by itself prove metabolic acidosis.

True metabolic acidosis is characterized by:

• Reduced serum bicarbonate
• Appropriate acidemia or compensatory respiratory response

The blood pH may occasionally be normal when another simultaneous acid-base disorder is present.

A blood gas and clinical context are therefore important.

Why an Anion Gap Exists

Plasma must remain electrically neutral.

Routine chemistry measures only some ions:

Measured Cation

• Sodium

Measured Anions

• Chloride
• Bicarbonate

Important unmeasured anions include:

• Albumin
• Phosphate
• Sulfate
• Organic acids

The normal apparent gap largely reflects:

Negatively charged albumin.

What Is a Normal Anion Gap?

The normal range depends on:

• Laboratory methodology
• Electrolyte analyzer
• Albumin concentration

With modern assays, a typical reference range without potassium is approximately:

8–12 mEq/L

rather than the older universal cutoff of <16 mEq/L.

Always use the:

Local laboratory reference range.

Correcting the Gap for Albumin

Hypoalbuminemia can conceal a dangerous high-anion-gap acidosis.

A commonly used correction is:

Corrected AG = measured AG + 2.5 × (4 − serum albumin in g/dL)

For example, an apparently normal gap in a severely hypoalbuminemic ICU patient may actually represent:

Significant accumulation of unmeasured acid.

The Modern Differential: GOLD MARK

The older MUDPILES mnemonic is historically useful but includes obsolete causes such as phenformin and paraldehyde.

A more useful modern mnemonic is:

GOLD MARK

• G – Glycols: ethylene glycol, propylene glycol
• O – Oxoproline (5-oxoproline/pyroglutamic acidosis)
• L – L-lactic acidosis
• D – D-lactic acidosis
• M – Methanol
• A – Aspirin/salicylates
• R – Renal failure
• K – Ketoacidosis

This should be combined with the patient’s clinical circumstances rather than used mechanically.

The Most Common Cause: Lactic Acidosis

Elevated lactate is among the most common causes of HAGMA.

Lactate accumulation may result from:

• Shock
• Sepsis
• Severe hypoxemia
• Tissue ischemia
• Cardiac arrest
• Generalized seizures
• Extreme agitation
• Severe anemia
• Mesenteric or limb ischemia

Drug- and toxin-related causes include:

• Metformin in susceptible patients
• Cyanide
• Carbon monoxide
• Propofol infusion syndrome
• Some antiretroviral drugs
• Beta-adrenergic stimulation

Type A vs Type B Lactic Acidosis

Type A

Caused primarily by impaired tissue oxygen delivery or utilization, such as:

• Shock
• Hypoxemia
• Severe ischemia

Type B

Occurs without obvious systemic hypoperfusion and may result from:

• Drugs
• Liver dysfunction
• Malignancy
• Thiamine deficiency
• Mitochondrial dysfunction

This distinction can help guide investigation.

Ketoacidosis

Important causes include:

• Diabetic ketoacidosis (DKA)
• Alcoholic ketoacidosis
• Starvation ketoacidosis
• SGLT2 inhibitor–associated euglycemic DKA

The most useful ketone assay is:

Serum beta-hydroxybutyrate.

Urine ketone strips primarily detect acetoacetate and may substantially underestimate early DKA.

Euglycemic Ketoacidosis

Do not exclude DKA solely because the glucose is not markedly elevated.

SGLT2 inhibitors can produce significant ketoacidosis with:

• Normal
• Mildly elevated

blood glucose.

A high gap with unexplained nausea, abdominal symptoms, or tachypnea in such a patient should prompt:

Beta-hydroxybutyrate testing.

Renal Failure

Advanced kidney failure causes accumulation of:

• Sulfate
• Phosphate
• Organic acids

producing:

High-anion-gap metabolic acidosis.

Earlier chronic kidney disease may instead produce a predominantly:

Normal-anion-gap acidosis.

Methanol Poisoning

Methanol is particularly important in ophthalmology because its toxic metabolite:

Formic acid

can damage the:

• Retina
• Optic nerve
• CNS

Methanol poisoning classically causes:

High-anion-gap metabolic acidosis + visual toxicity.

Ocular Clues to Methanol Poisoning

Patients may report:

• Blurred vision
• “Snowfield” vision
• Photophobia
• Central visual loss
• Dyschromatopsia
• Complete blindness in severe poisoning

Examination may reveal:

• Reduced acuity
• RAPD if asymmetric
• Optic disc hyperemia or edema early
• Subsequent optic atrophy

Unexplained visual symptoms combined with severe metabolic acidosis should immediately raise concern for:

Methanol exposure.

Ethylene Glycol Poisoning

Ethylene glycol is metabolized to toxic acids including:

• Glycolic acid
• Oxalic acid

It can cause:

• Severe metabolic acidosis
• CNS depression
• Hypocalcemia
• Acute kidney injury

Calcium oxalate crystals may appear in urine but:

Their absence does not exclude poisoning.

Salicylate Poisoning

Salicylate toxicity classically produces a:

Mixed acid-base disorder.

Early:

Respiratory alkalosis

from direct respiratory-center stimulation.

Later:

High-anion-gap metabolic acidosis

from organic acid accumulation.

Therefore a near-normal pH can conceal severe toxicity because the two processes may offset each other.

Salicylate Clinical Clues

Important features include:

• Tinnitus
• Tachypnea
• Nausea/vomiting
• Diaphoresis
• Fever
• Agitation
• Delirium

Severe poisoning can cause:

• Pulmonary edema
• Seizures
• Coma

A serum salicylate concentration should be measured when the cause of HAGMA is unexplained.

Isoniazid

Isoniazid overdose can produce:

• Refractory seizures
• Lactic acidosis
• Coma

The specific antidote is:

Pyridoxine (vitamin B6).

Persistent seizures after suspected isoniazid ingestion are a major diagnostic clue.

Iron Poisoning

Severe iron toxicity can produce:

• Vomiting
• Hematemesis
• Abdominal pain
• Shock
• HAGMA
• Hepatic failure

A serum iron concentration and toxicology consultation are appropriate when suspected.

Acetaminophen and the Anion Gap

Two different mechanisms are relevant.

Massive Acute Overdose

May produce early:

Lactic acidosis

from mitochondrial dysfunction.

Repeated or Chronic Exposure in Susceptible Patients

Can cause:

5-oxoproline (pyroglutamic) acidosis

particularly with:

• Malnutrition
• Sepsis
• Renal dysfunction
• Chronic illness

This is the O in GOLD MARK.

Toluene

Toluene exposure may cause acidosis, especially in solvent abuse.

However, the classic disturbance is often:

Hyperchloremic normal-anion-gap metabolic acidosis

because hippurate is rapidly excreted with sodium and potassium.

An elevated gap may occur earlier or with severe exposure.

Carbon Monoxide and Cyanide

Both can produce:

Lactic acidosis through impaired cellular oxygen utilization.

Carbon Monoxide

May cause:

• Headache
• Confusion
• Syncope
• Chest pain

Pulse oximetry can be misleading.

Diagnosis relies on:

Carboxyhemoglobin measurement by co-oximetry.

Cyanide

Can cause:

• Abrupt cardiovascular collapse
• Severe lactic acidosis
• Altered mental status

A very high unexplained lactate in the appropriate exposure setting should raise concern.

Do Not Depend on Characteristic Odors

Older descriptions emphasize:

• Bitter almonds for cyanide
• Rotten eggs for hydrogen sulfide

These are unreliable because:

• Many individuals cannot detect them
• Odor may disappear rapidly
• Exposure itself may impair olfaction

Diagnosis should not depend on smell.

The Osmolal Gap

The osmolal gap is useful when toxic alcohol exposure is suspected.

It is:

Measured serum osmolality − calculated serum osmolality.

A commonly used calculation in conventional US units is:

Calculated osmolality ≈ 2 × Na + glucose/18 + BUN/2.8 + ethanol/4.6

Exact formulas vary.

Why Toxic Alcohols Produce an Osmolal Gap

Methanol and ethylene glycol themselves are:

Osmotically active parent alcohols.

Soon after ingestion:

• Osmolal gap rises
• Anion gap may still be normal

As metabolism proceeds:

• Parent alcohol concentration falls
• Osmolal gap may normalize
• Toxic organic acids accumulate
• Anion gap rises

Thus the two gaps can evolve in opposite directions.

A Normal Osmolal Gap Does Not Exclude Toxic Alcohol Poisoning

This is a critical principle.

A patient presenting late after methanol or ethylene glycol ingestion may have:

• Severe HAGMA
• Organ toxicity
• Normal or minimally increased osmolal gap

because the parent alcohol has already been converted to acidic metabolites.

First-Line Laboratory Evaluation

In unexplained HAGMA, useful initial tests generally include:

• Repeat serum electrolytes
• Glucose
• Creatinine and BUN
• Serum lactate
• Serum beta-hydroxybutyrate
• Blood gas
• Serum osmolality
• Salicylate level
• Acetaminophen level

Additional testing should be guided by the clinical context.

Venous vs Arterial Blood Gas

For most metabolic acid-base assessment:

Venous blood gas is usually adequate

for evaluating:

• pH
• Bicarbonate
• PCO₂ trend

Arterial sampling is more useful when precise assessment of:

Oxygenation

is needed.

Toxic Alcohol Levels

When available, directly measure:

• Methanol
• Ethylene glycol

But treatment should not be delayed while awaiting these levels when clinical suspicion is high.

Urinalysis

Useful findings may include:

• Ketones
• Glucose
• Hematuria
• Myoglobin
• Oxalate crystals

But urinary calcium oxalate crystals in ethylene glycol poisoning have:

Insufficient sensitivity to exclude poisoning when absent.

ECG

Obtain an ECG when overdose is possible.

It can reveal:

• QRS prolongation
• QT prolongation
• Dysrhythmias
• Ischemic changes

that may identify otherwise unsuspected cardiotoxic ingestion.

Assessing Respiratory Compensation

A patient with metabolic acidosis should compensate by lowering PCO₂.

Expected PCO₂ can be estimated using:

Winter’s formula:

Expected PCO₂ = 1.5 × HCO₃⁻ + 8 ± 2

If measured PCO₂ is:

• Higher than expected → additional respiratory acidosis
• Lower than expected → additional respiratory alkalosis

This is especially important in poisoned patients.

Why Respiratory Compensation Matters

A severely acidotic patient may be sustaining life by maintaining:

Very high minute ventilation.

Loss of that compensation during:

• Sedation
• Intubation
• Mechanical ventilation

can cause a sudden rise in PCO₂ and a catastrophic fall in pH.

This is especially dangerous in:

Salicylate poisoning.

Delta Gap and Mixed Metabolic Disorders

A high anion gap does not exclude a second metabolic disorder.

Comparing the increase in anion gap with the fall in bicarbonate can identify:

• Concurrent normal-gap acidosis
• Concurrent metabolic alkalosis

A commonly used concept is the:

Delta ratio.

This is useful in complicated ICU or toxicology cases but should be interpreted alongside the clinical picture.

Initial Management Priorities

Management begins with:

1. Airway and breathing when necessary
2. Circulatory support
3. Correction of hypoxemia
4. Identification of the acid source
5. Specific antidotal therapy when indicated
6. Serial reassessment

The underlying cause must be treated rather than simply correcting the laboratory bicarbonate value.

Important Modern Correction: The “Coma Cocktail” Is Obsolete

Older protocols routinely gave:

• Oxygen
• Thiamine
• Glucose
• Naloxone

to any patient with altered mental status.

Modern therapy is targeted.

Use:

• Glucose for documented or strongly suspected hypoglycemia
• Naloxone for suspected opioid-induced respiratory depression
• Thiamine in patients at risk of deficiency
• Oxygen for hypoxemia or carbon monoxide poisoning

Do not delay glucose in a hypoglycemic patient while waiting to administer thiamine.

Fomepizole for Toxic Alcohol Poisoning

Fomepizole inhibits alcohol dehydrogenase and prevents conversion of:

• Methanol → formic acid
• Ethylene glycol → glycolic/oxalic acids

It is the preferred antidote when toxic alcohol poisoning is suspected.

Do Not Wait for Confirmation

If there is a credible toxic alcohol exposure plus findings such as:

• Unexplained HAGMA
• Elevated osmolal gap
• Visual symptoms
• Acute kidney injury

Start fomepizole while confirmatory testing is pending.

Delaying treatment can cause irreversible:

• Blindness
• Renal failure
• Death

Ethanol as an Antidote

Ethanol also competes for alcohol dehydrogenase.

It remains an alternative when:

Fomepizole is unavailable.

However, fomepizole is preferred because ethanol is harder to dose and causes:

• Intoxication
• Hypoglycemia
• CNS depression
• Monitoring difficulties

Hemodialysis for Toxic Alcohols

Hemodialysis rapidly removes:

• Parent toxic alcohol
• Toxic metabolites

and corrects severe acidosis.

It should be considered in methanol or ethylene glycol poisoning with features such as:

• Severe metabolic acidosis
• Significant end-organ toxicity
• Visual toxicity from methanol
• Acute kidney injury from ethylene glycol
• Very high toxic alcohol concentration
• Clinical deterioration despite antidote

Exact thresholds depend on current toxicology protocols.

Folate Therapy in Methanol Poisoning

Folinic acid or folic acid may be administered because it facilitates metabolism of:

Formate to nontoxic products.

It is adjunctive to:

• Fomepizole
• Acidosis management
• Dialysis when indicated

Pyridoxine and Thiamine in Ethylene Glycol

Pyridoxine and thiamine are sometimes given as adjuncts to promote metabolism toward:

Less toxic metabolites.

They do not replace:

• Fomepizole
• Dialysis when indicated

Sodium Bicarbonate

Bicarbonate is not routine treatment for every lactic acidosis.

The priority is correcting the underlying:

• Shock
• Hypoxia
• Sepsis
• Ischemia

However, bicarbonate has important roles in selected severe acid-base disorders and toxicologic emergencies.

When Bicarbonate Is Particularly Important

Examples include:

• Salicylate poisoning, where serum and urinary alkalinization reduces tissue penetration and enhances elimination
• Severe methanol poisoning with marked acidemia
• Severe ethylene glycol poisoning with marked acidemia
• Selected cases of profound acidemia with cardiovascular instability

Use should be guided by the specific disorder.

Salicylate Alkalinization

In significant salicylate toxicity:

IV sodium bicarbonate is used to alkalinize serum and urine.

Increasing blood pH reduces movement of salicylate into:

• Brain
• Other tissues

Urinary alkalinization also increases salicylate excretion.

Intubation in Salicylate Poisoning

Intubation can be dangerous because even brief hypoventilation causes:

• Rising PCO₂
• Falling pH
• Increased nonionized salicylate
• Increased CNS penetration

If intubation is unavoidable:

Maintain or exceed the patient’s pre-intubation minute ventilation as closely as possible.

Decontamination – Major Modern Correction

Induced emesis is not recommended.

Routine gastric lavage is also:

Not recommended.

Gastric lavage is now reserved for exceptional, potentially lethal ingestions when:

• Presentation is very early
• The airway is protected
• Expert toxicology guidance supports it

Activated Charcoal

A single dose of activated charcoal may be considered when:

• The ingestion is potentially toxic
• The substance binds charcoal
• Presentation is sufficiently early
• Airway protection is adequate

It is not useful for all toxicants.

Substances Poorly Adsorbed by Activated Charcoal

Activated charcoal is generally ineffective for substances such as:

• Methanol
• Ethylene glycol
• Iron
• Lithium
• Many caustics

Therefore charcoal should not delay specific treatment for these exposures.

Why Persistent HAGMA Requires Escalation

Persistent unexplained HAGMA may represent:

• Occult shock
• Mesenteric ischemia
• Toxic alcohol poisoning
• Salicylate toxicity
• Ketoacidosis
• Severe renal failure

A patient whose gap remains elevated or continues rising requires:

Repeated investigation rather than passive observation.

Serial Monitoring

Depending on severity, follow:

• Electrolytes
• Anion gap
• Blood gas
• Lactate
• Glucose
• Beta-hydroxybutyrate
• Renal function
• Osmolality

Toxin concentrations should be repeated when clinically appropriate.

When Critical Care Is Needed

ICU-level management should be considered for:

• Severe acidemia
• Hemodynamic instability
• Altered mental status
• Respiratory compromise
• Seizures
• Suspected toxic alcohol poisoning
• Severe salicylate poisoning
• Need for dialysis

Persistent unexplained HAGMA generally warrants:

Hospital admission and continued evaluation.

Common Diagnostic Pitfalls

Important errors include:

• Using a fixed AG >16 threshold regardless of laboratory reference range
• Failing to correct the gap for low albumin
• Assuming a normal osmolal gap excludes toxic alcohol poisoning
• Missing euglycemic DKA
• Failing to obtain a salicylate concentration
• Attributing all lactate elevation to sepsis without considering toxins or ischemia
• Treating the bicarbonate number instead of the underlying disorder
• Intubating a profoundly acidotic patient without preserving compensatory ventilation

Ophthalmic Red Flag

The most important ophthalmic association is:

Methanol toxicity.

The combination of:

• Unexplained high-anion-gap metabolic acidosis
• Possible toxic alcohol exposure
• Acute bilateral visual blurring or visual loss

should trigger immediate treatment for suspected methanol poisoning while definitive levels are pending.

Optic nerve injury can become:

Irreversible.

High-Yield Takeaways

• High-anion-gap metabolic acidosis reflects accumulation of unmeasured acids and can indicate a life-threatening metabolic or toxicologic emergency.
• Calculate the gap as Na − (Cl + HCO₃), but use the laboratory’s own normal range rather than an outdated universal cutoff of 16 mEq/L.
• Correct the anion gap for hypoalbuminemia, approximately adding 2.5 mEq/L for every 1 g/dL that albumin is below 4 g/dL.
• The modern differential is summarized by GOLD MARK: Glycols, Oxoproline, L-lactate, D-lactate, Methanol, Aspirin, Renal failure, Ketoacidosis.
• Lactic acidosis, ketoacidosis, and renal failure are among the most common causes.
• Salicylate poisoning classically causes respiratory alkalosis plus high-anion-gap metabolic acidosis.
• Measure beta-hydroxybutyrate when ketoacidosis is suspected; urine ketones may underestimate early disease.
• SGLT2 inhibitors can cause euglycemic DKA, so a normal glucose does not exclude ketoacidosis.
• Methanol causes formate toxicity and optic neuropathy; visual symptoms plus HAGMA should be treated as methanol poisoning until proven otherwise.
• Ethylene glycol causes severe acidosis, hypocalcemia, and acute kidney injury; urinary oxalate crystals are supportive but not required.
• A high osmolal gap supports toxic alcohol exposure, but a normal osmolal gap does not exclude late methanol or ethylene glycol poisoning.
• Early toxic alcohol poisoning may have a high osmolal gap with little acidosis; later poisoning may have a high anion gap with a normalizing osmolal gap.
• Initial evaluation should usually include electrolytes, blood gas, lactate, beta-hydroxybutyrate, glucose, renal function, measured serum osmolality, salicylate level, and acetaminophen level.
• Use Winter’s formula to determine whether respiratory compensation is appropriate.
• Fomepizole is the preferred antidote for suspected methanol or ethylene glycol poisoning, and treatment should not wait for confirmatory levels when suspicion is high.
• Severe toxic alcohol poisoning may require urgent hemodialysis.
• Sodium bicarbonate is particularly important in salicylate toxicity and severe toxic-alcohol acidemia, but it is not routine treatment for every lactic acidosis.
• Induced emesis is obsolete, and gastric lavage is now extremely rarely indicated.
• Activated charcoal does not effectively adsorb methanol, ethylene glycol, iron, or lithium.
• The traditional indiscriminate “coma cocktail” is outdated; antidotes and supportive treatment should be targeted to the suspected problem.
• During intubation of a severely acidotic patient, preserve compensatory high minute ventilation; loss of hyperventilation can cause catastrophic acidemia, particularly in salicylate poisoning.
• Persistent, unexplained HAGMA warrants serial reassessment, hospital admission, and early toxicology/nephrology involvement when indicated.

High-Yield Takeaways

Toxicology – Acute Kidney Injury (AKI) in Poisoning

Definition

Acute kidney injury (AKI), historically called acute renal failure, is an abrupt decline in renal function resulting in impaired regulation of fluid, electrolytes, acid-base balance, and waste products.

Related terms:

• Azotemia: increased BUN and/or serum creatinine
• Acute tubular injury/necrosis (ATI/ATN): damage and dysfunction of renal tubular cells
• Acute interstitial nephritis (AIN): inflammatory injury involving the renal interstitium
• Nephrotic syndrome: heavy proteinuria associated with hypoalbuminemia, edema, and often hyperlipidemia

Major Mechanisms

Toxin-associated AKI can be divided into three broad categories:

1. Prerenal AKI – decreased renal perfusion

• Dehydration
• Vomiting or diarrhea
• Hemorrhage
• Hypotension or shock
• Drug-induced cardiac dysfunction
• Altered renal vascular tone

Examples of drugs that can impair renal perfusion include NSAIDs, ACE inhibitors, and calcineurin inhibitors.

2. Intrinsic Renal Injury – direct kidney damage

Important mechanisms include:

• Acute tubular injury
• Acute interstitial nephritis
• Glomerular injury
• Pigment nephropathy from rhabdomyolysis or hemolysis
• Crystal nephropathy

Representative nephrotoxic exposures include:

• Aminoglycosides
• Amphotericin B
• Cisplatin
• Cyclosporine
• Ethylene glycol
• Methotrexate
• Heavy metals
• Certain mushrooms
• Radiographic contrast in susceptible patients

3. Postrenal AKI – urinary obstruction

Possible causes include:

• Drug or metabolite crystallization
• Calcium or uric acid stones
• Anticholinergic urinary retention
• Other mechanical urinary obstruction

Risk Factors

The risk of toxin-associated AKI increases with:

• Pre-existing kidney disease
• Dehydration or hypovolemia
• Simultaneous exposure to several nephrotoxic agents
• Severe systemic poisoning
• Prolonged hypotension

Clinical Features

AKI may initially produce few symptoms.

Possible findings include:

• Reduced urine output
• Fluid retention
• Peripheral or pulmonary edema
• Hypertension
• Nausea and vomiting
• Weakness
• Confusion in severe uremia

Major complications include:

• Hyperkalemia
• Metabolic acidosis
• Fluid overload
• Uremia

Urine output can be reduced, normal, or occasionally increased, so normal urine production does not exclude AKI.

Toxicologic Clues

Certain findings can suggest the underlying exposure:

• Anion-gap metabolic acidosis + calcium oxalate crystalluria → ethylene glycol
• Rhabdomyolysis → sympathomimetics, prolonged coma/immobility, seizures, carbon monoxide, and several other toxic exposures
• Microcytic anemia + basophilic stippling → chronic lead exposure
• GI injury + renal failure → consider heavy metals and other systemic toxicants
• Tremor, neurologic abnormalities + renal dysfunction → consider lithium in the appropriate setting

These findings are clues rather than diagnostic by themselves.

Urinalysis and Urine Sediment

Urine microscopy can help determine the mechanism of renal injury.

Prerenal AKI

• Often relatively bland urine sediment
• Hyaline casts may occur

Acute tubular injury

• Muddy-brown granular casts
• Renal tubular epithelial cells

Glomerulonephritis

• Hematuria
• Proteinuria
• Red blood cell casts

Pigment nephropathy

• Urine dipstick positive for blood with few or no red blood cells on microscopy suggests myoglobin or free hemoglobin

Crystal nephropathy

• Calcium oxalate crystals may support ethylene glycol exposure in the appropriate clinical setting.
• Uric acid crystals can occur with uric acid nephropathy.

Laboratory Evaluation

Important tests may include:

• Serum creatinine and BUN
• Electrolytes
• Bicarbonate
• Calcium, magnesium, and phosphate
• Urinalysis with microscopy
• Urine output monitoring
• Creatine kinase when rhabdomyolysis is suspected
• ECG when hyperkalemia is possible
• Targeted toxicant concentrations when clinically indicated

Serial creatinine measurements are often more informative than a single value because creatinine may rise after the kidney injury has already occurred.

FENa and Other Urine Indices

Traditionally:

• Low fractional excretion of sodium (FENa) supports a prerenal process.
• Higher FENa may support intrinsic tubular injury.

However, these are supportive rather than definitive tests. Diuretics, chronic kidney disease, sepsis, and several other conditions can make FENa misleading.

Clinical context and urine sediment are therefore important.

Management

Treatment focuses on both the cause of AKI and its complications:

• Stop nephrotoxic substances when possible.
• Treat the underlying poisoning.
• Restore appropriate intravascular volume when hypovolemia is present.
• Maintain adequate renal perfusion.
• Carefully monitor fluid intake and urine output.
• Correct clinically important electrolyte and acid-base abnormalities.
• Treat rhabdomyolysis or other underlying causes when present.

A specific antidote should be given when one exists for the responsible toxicant.

Dialysis

Renal replacement therapy may be required for complications such as:

• Refractory hyperkalemia
• Severe metabolic acidosis
• Pulmonary edema or fluid overload
• Significant uremic complications

In toxicology, dialysis may also be indicated specifically to remove a dialyzable poison, such as lithium, methanol, ethylene glycol, or salicylate, even before conventional indications for dialysis develop.

Important Modern Correction

Older references sometimes recommend “renal-dose” dopamine to preserve kidney function.

This practice is no longer recommended because low-dose dopamine has not been shown to prevent or treat AKI and can cause adverse effects.

Loop diuretics may help manage volume overload, but they do not reverse intrinsic kidney injury or improve renal recovery simply by increasing urine output.

Key Points

• Toxin-related AKI may be prerenal, intrinsic renal, or postrenal.
• Muddy-brown granular casts → acute tubular injury.
• RBC casts → glomerular disease.
• Positive urine blood with few/no RBCs → consider myoglobinuria or hemoglobinuria.
• Hyperkalemia, metabolic acidosis, and fluid overload are major complications.
• Creatinine may lag behind the actual renal injury.
• FENa can support the diagnosis but should not be interpreted in isolation.
• Treat the underlying poisoning and discontinue nephrotoxins whenever possible.
• “Renal-dose” dopamine should not be used to prevent or treat AKI.

Toxicology – Drug Screening

Definition

Drug screening detects selected drugs or their metabolites in urine or blood.

In toxicology, drug screens are mainly an adjunct to the history, physical examination, vital signs, ECG, and targeted laboratory testing. They should not replace recognition of the patient’s clinical toxidrome.

The substances included in a drug screen vary considerably between laboratories.

Urine Drug Screening

Urine is commonly used because many drugs and their metabolites become concentrated in urine and remain detectable longer than in blood.

The major testing methods are:

• Immunoassay
• Chromatographic techniques
• Mass spectrometry for more definitive identification

Immunoassay

Mechanism

Antibodies recognize a particular drug or drug class. The resulting reaction is detected using an enzymatic or other laboratory method.

Advantages

• Rapid
• Relatively inexpensive
• Minimal specimen preparation
• Widely available

Limitations

• Detects only substances included in the assay
• Cross-reactivity can produce false-positive results
• Some members of a drug class may not be detected, producing false-negative results

For example, a routine opioid immunoassay may fail to detect certain synthetic or semisynthetic opioids unless specific assays are ordered.

Chromatography

Chromatographic methods separate substances according to their chemical properties.

Techniques include:

• Gas chromatography
• Liquid chromatography

These methods can identify a broader range of compounds than many routine immunoassays but generally require more specialized equipment and expertise.

Mass Spectrometry

Mass spectrometry is commonly combined with chromatography, such as:

• GC-MS: gas chromatography–mass spectrometry
• LC-MS/MS: liquid chromatography–tandem mass spectrometry

The technique identifies compounds based on characteristic molecular properties and provides much greater specificity than routine immunoassay screening.

It is particularly useful when definitive identification is required, although availability and turnaround time vary.

Targeted Serum Testing

For many important poisonings, a specific quantitative blood concentration is more useful than a broad urine drug screen.

Important examples include:

• Acetaminophen
• Salicylates
• Lithium
• Ethanol
• Methanol
• Ethylene glycol
• Selected anticonvulsants
• Theophylline

The appropriate test depends on the suspected exposure.

Clinical Uses

Routine broad toxicology screening is usually unnecessary in a patient whose history and clinical findings already establish the diagnosis.

Testing may be useful when:

• Altered mental status has no clear explanation.
• The reported ingestion does not match the clinical findings.
• Multiple or unknown substances may have been involved.
• Definitive identification would meaningfully change management.

The clinician should ideally know how the result will affect treatment before ordering the test.

Interpreting a Positive Result

A positive urine drug screen indicates that the assay detected a drug, metabolite, or cross-reacting substance.

It does not necessarily prove:

• Current intoxication
• The dose taken
• When the substance was used
• That the detected drug caused the patient’s current symptoms

Many substances remain detectable in urine after their clinical effects have resolved.

Interpreting a Negative Result

A negative drug screen does not exclude poisoning.

Possible explanations include:

• The drug is not included in the panel.
• The concentration is below the assay’s detection threshold.
• The specimen was collected too early.
• The urine is very dilute.
• The assay does not reliably detect that particular drug.
• The specimen was altered or substituted in nonclinical testing situations.

Therefore:

Negative screen ≠ no toxic exposure.

Important Limitations

Many clinically important toxicants are poorly assessed by routine urine drug screens and require specific testing or clinical diagnosis.

Examples include:

• Lithium
• Iron
• Heavy metals
• Toxic alcohols
• Cyanide
• Hydrocarbons

The exact limitations depend on the laboratory and assay being used.

Confirmatory Testing

When a screening result has major legal, occupational, forensic, or other consequences, an initial immunoassay result generally requires more specific confirmatory testing, commonly using mass-spectrometric techniques.

Key Points

• Treat the patient, not the drug screen.
• Urine immunoassays are convenient but have important false-positive and false-negative limitations.
• A positive urine result does not establish active intoxication.
• A negative result does not rule out poisoning.
• Targeted quantitative serum concentrations are more useful for several major toxicants.
• Always determine which substances the local laboratory panel actually detects.
• Drug screening is most valuable when the result can answer a specific clinical question or alter management.

Toxicology – Enhanced Elimination Techniques III

Peritoneal Dialysis

Mechanism of Action

Dialysis fluid is placed into the peritoneal cavity, and the peritoneal membrane acts as a semipermeable barrier.

Toxicants diffuse from the bloodstream into the dialysate, which is subsequently drained and replaced.

Substances are more readily removed when they are:

• Water soluble
• Minimally protein bound
• Low molecular weight
• Distributed mainly within the bloodstream

Potential Indications

Peritoneal dialysis has historically been used for selected severe poisonings, particularly when hemodialysis is unavailable or technically impossible.

Examples have included:

• Methanol
• Ethylene glycol
• Salicylates
• Theophylline

It has also been considered in infants or neonates when other extracorporeal techniques cannot be performed.

Current Role

Peritoneal dialysis removes most toxicants much more slowly than hemodialysis. Modern intermittent hemodialysis is therefore preferred for most poisonings requiring extracorporeal removal.

Complications

• Peritonitis
• Bowel or abdominal-organ injury
• Fluid and electrolyte abnormalities
• Hypotension
• Volume overload
• Catheter-related complications

Previous abdominal surgery or adhesions can make treatment technically difficult.

Key Point

Peritoneal dialysis now has a very limited role in poisoning and is generally considered only when more effective extracorporeal techniques are unavailable.

Urinary Alkalinization

Mechanism of Action

Urinary alkalinization increases urinary elimination of certain weak acids.

Increasing urine pH causes these substances to become more ionized within the renal tubule. The ionized molecules cannot readily diffuse back across cell membranes, producing “ion trapping” and increasing urinary excretion.

Major Indication

The most important toxicologic indication is:

• Salicylate poisoning

Urinary alkalinization increases renal salicylate elimination and also helps maintain alkalemia, which reduces movement of salicylate into tissues such as the brain.

Other substances whose elimination can theoretically or measurably increase include:

• Phenobarbital
• Chlorpropamide
• 2,4-D herbicides

However, clinical benefit is best established for salicylate toxicity.

Urine alkalinization is also used during high-dose methotrexate therapy to reduce renal precipitation and nephrotoxicity, although this is primarily an oncologic rather than poisoning indication.

Monitoring / Complications

Important problems include:

• Hypokalemia
• Metabolic alkalosis
• Volume overload
• Hypernatremia
• Hypomagnesemia

Adequate potassium is particularly important because hypokalemia makes successful urine alkalinization more difficult.

Patients with severe salicylate poisoning may require hemodialysis rather than alkalinization alone.

Key Point

Think of urinary alkalinization primarily as an enhanced elimination technique for salicylates.

Urinary Acidification

Mechanism of Action

Historically, urine was acidified in an attempt to increase elimination of weakly basic drugs through ion trapping.

Current Role

There are no routine toxicologic indications for urinary acidification.

Potential harms outweigh the limited improvement in drug elimination.

Complications can include:

• Systemic metabolic acidosis
• Worsening kidney injury
• Increased precipitation of myoglobin or hemoglobin within renal tubules
• Electrolyte disturbances

For this reason, urinary acidification is considered an obsolete enhanced-elimination technique.

Key Points

• Peritoneal dialysis: rarely used because hemodialysis generally clears toxicants more efficiently.
• Urinary alkalinization: particularly important for salicylate poisoning through ion trapping of weak acids.
• Urinary acidification: no longer recommended because its risks outweigh its benefits.
• Severe poisoning should not be managed according to pharmacokinetic principles alone; the patient’s clinical condition determines whether more definitive treatment such as hemodialysis is required.

Toxicology – Enhanced Elimination Techniques II

Hemofiltration

Mechanism of Action

Hemofiltration passes blood through a semipermeable membrane, removing water and dissolved substances by convection.

It can remove:

• Certain toxicants
• Electrolytes
• Urea and creatinine
• Some therapeutic medications

Continuous renal replacement techniques provide slower, prolonged clearance. Because treatment continues while a toxicant redistributes from tissues into the bloodstream, they may reduce post-treatment rebound.

Potential Indications

Hemofiltration may be considered for selected severe poisonings involving substances with:

• Relatively small volume of distribution
• Low endogenous clearance
• Suitable molecular size

It has occasionally been used for substances such as:

• Lithium
• Certain aminoglycosides

However, for many dialyzable poisons, intermittent hemodialysis provides substantially faster clearance and is preferred when the patient can tolerate it.

Advantages

• Continuous and gradual removal
• Better tolerated than intermittent hemodialysis in some hemodynamically unstable patients
• Useful when continuous renal replacement therapy is already required for renal failure

Limitations / Complications

• Slower toxicant clearance than conventional hemodialysis
• Fluid and electrolyte disturbances
• Vascular-access complications
• Bleeding or anticoagulation-related complications

Key Point

Modern continuous renal replacement therapy can be useful when conventional hemodialysis is poorly tolerated, but slower clearance makes it unsuitable as a direct substitute for rapid hemodialysis in many severe poisonings.

Multiple-Dose Activated Charcoal (MDAC)

Mechanism of Action

Multiple-dose activated charcoal involves repeated administration of charcoal to increase elimination of certain already-absorbed toxicants.

It works mainly through two mechanisms:

• Interrupting enterohepatic/enteric recycling: drugs secreted back into the GI tract are bound by charcoal before they can be reabsorbed.
• “Gastrointestinal dialysis”: some drugs diffuse from the bloodstream across the intestinal wall into the GI lumen, where charcoal traps them.

This maintains a concentration gradient favoring movement of the toxicant from blood into the intestine.

Best Candidates

MDAC is most effective for drugs that:

• Bind strongly to activated charcoal
• Have relatively small volumes of distribution
• Remain in the circulation long enough for enhanced GI elimination

The classic drugs for which MDAC may meaningfully enhance elimination include:

• Carbamazepine
• Dapsone
• Phenobarbital
• Quinine
• Theophylline

Enhanced elimination has been demonstrated for several other substances, but evidence that this improves clinical outcomes is more limited.

Contraindications

MDAC should generally be avoided with:

• Unprotected airway or high aspiration risk
• Ileus
• Bowel obstruction
• GI perforation

Complications

• Vomiting
• Aspiration pneumonitis
• Constipation
• Bowel obstruction or charcoal impaction
• Fluid and electrolyte disturbances, particularly when cathartics are repeatedly administered

Important Precaution

Repeated cathartic administration should be avoided because it can cause dangerous fluid and electrolyte losses, especially in children.

Key Points

• MDAC is an enhanced elimination technique, not simply repeated GI decontamination.
• Remember the classic MDAC drugs: carbamazepine, dapsone, phenobarbital, quinine, and theophylline.
• The airway must be protected before charcoal is considered in a patient with significant CNS depression.
• Ileus or bowel obstruction substantially increases the risk of complications.
• Continuous hemofiltration provides slower clearance than intermittent hemodialysis but may be useful when hemodynamic instability limits conventional dialysis.

Toxicology – Enhanced Elimination Techniques I

Enhanced elimination techniques are used in selected severe poisonings to increase removal of a toxicant from the body or temporarily support the patient while normal elimination occurs. Choice depends on the toxicant’s pharmacokinetics and the patient’s clinical condition.

Cardiopulmonary Bypass (CPB)

Mechanism of Action

Cardiopulmonary bypass primarily provides temporary circulatory and respiratory support rather than directly removing the poison.

By maintaining organ perfusion during otherwise refractory cardiovascular collapse, it can provide time for:

• Hepatic metabolism
• Renal elimination
• Redistribution of the toxicant
• Recovery from reversible cardiotoxicity

Modern extracorporeal support such as VA-ECMO has largely assumed this role in many severe poisonings.

Indications

May be considered for otherwise refractory cardiovascular collapse caused by a potentially reversible poisoning, particularly when conventional resuscitation has failed.

It has historically been reported in severe cardiotoxic drug poisonings such as:

• Flecainide
• Lidocaine and other local anesthetics

Limitations / Complications

• Requires specialized personnel and equipment
• Major vascular access is required
• Bleeding and anticoagulation complications can occur
• It does not necessarily provide substantial direct toxicant clearance

Key Point

Think of extracorporeal circulatory support as a way to “buy time” for recovery and endogenous drug elimination, rather than as a conventional dialysis technique.

Exchange Transfusion

Mechanism of Action

The patient’s blood is progressively removed and replaced with donor blood or blood components.

This can remove toxicants that are largely confined to the intravascular compartment and replace damaged blood cells.

Possible Indications

Rarely considered for:

• Severe methemoglobinemia refractory to standard therapy
• Selected severe poisoning in neonates or infants when other extracorporeal techniques are unsuitable
• Severe toxin-induced hemolysis in exceptional circumstances

Limitations / Complications

• Transfusion reactions
• Hypothermia
• Hypotension
• Hypocalcemia
• Coagulopathy
• Thrombocytopenia
• Infection and other transfusion-related complications

Key Point

Exchange transfusion is now an uncommon, specialized rescue technique and is most useful when the relevant toxicant or toxic effect is concentrated within the blood.

Hemodialysis

Mechanism of Action

Blood passes along a semipermeable membrane, allowing toxic substances to diffuse into the dialysate.

A toxicant is generally easier to dialyze when it has:

• Low molecular weight
• Low protein binding
• Small volume of distribution
• High water solubility

Modern high-flux dialysis can remove some substances that older dialysis systems handled poorly.

Important Dialyzable Poisons

Hemodialysis has an established role in selected severe poisonings involving:

• Methanol
• Ethylene glycol
• Lithium
• Salicylates
• Theophylline

It can also simultaneously correct:

• Severe metabolic acidosis
• Electrolyte abnormalities
• Fluid disturbances

Dialysis may occasionally be used for other toxicants, but increased clearance alone does not mean that dialysis improves clinical outcomes enough to justify the procedure.

Complications

• Hypotension
• Fluid shifts
• Electrolyte abnormalities
• Vascular-access complications
• Bleeding related to anticoagulation

Important Considerations

Some antidotes, including fomepizole, can themselves be removed during dialysis, so antidote regimens may require adjustment under specialist guidance.

After dialysis, the serum toxicant concentration may occasionally rebound because drug stored in tissues redistributes back into the bloodstream. Additional treatment may therefore be required.

Key Point

Hemodialysis is most useful when the poison remains substantially in the bloodstream and can readily cross the dialysis membrane.

Hemoperfusion

Mechanism of Action

Instead of relying primarily on diffusion across a membrane, hemoperfusion passes blood through a cartridge containing an adsorbent material, historically activated charcoal or resin.

The toxicant binds to the cartridge and is removed from circulation.

Potentially Suitable Toxicants

Hemoperfusion works best when a substance:

• Has a relatively small volume of distribution
• Has low endogenous clearance
• Can be effectively adsorbed by the cartridge

Historically important examples include:

• Theophylline
• Carbamazepine
• Phenobarbital

Limitations / Complications

• Thrombocytopenia
• Bleeding and anticoagulation complications
• Vascular-access complications
• Hypotension
• Possible rebound after treatment

Unlike hemodialysis, hemoperfusion does not effectively correct metabolic acidosis, electrolyte abnormalities, or fluid disturbances.

Current Role

Hemoperfusion is used much less frequently today because modern hemodialysis is more readily available and effective for many dialyzable poisonings.

Key Points

• CPB/VA-ECMO: supports circulation while the body clears the poison.
• Exchange transfusion: replaces circulating blood and is rarely used.
• Hemodialysis: removes small, water-soluble, relatively unbound toxicants and simultaneously corrects acid-base/electrolyte problems.
• Hemoperfusion: directly adsorbs circulating toxicants but has a more limited modern role.
• Decisions about extracorporeal treatment depend on the patient’s clinical severity as well as toxicant characteristics, rather than serum concentration alone.
• Early consultation with toxicology and nephrology/critical-care specialists is important when extracorporeal treatment may be required.

Cardiopulmonary bypass primarily provides temporary circulatory and respiratory support rather than directly removing the poison. By maintaining organ perfusion during otherwise refractory cardiovascular collapse, it can provide time for:  Hepatic metabolism Renal elimination Redistribution of the toxicant Recovery from reversible cardiotoxicity  Modern extracorporeal support such as VA-ECMO has largely assumed this role in many severe poisonings. Indications

May be considered for otherwise refractory cardiovascular collapse caused by a potentially reversible poisoning, particularly when conventional resuscitation has failed. It has historically been reported in severe cardiotoxic drug poisonings such as:  Flecainide Lidocaine and other local anesthetics  Limitations / Complications  Requires specialized personnel and equipment Major vascular access is required Bleeding and anticoagulation complications can occur It does not necessarily provide substantial direct toxicant clearance  Key Point

Think of extracorporeal circulatory support as a way to “buy time” for recovery and endogenous drug elimination, rather than as a conventional dialysis technique.

Exchange Transfusion Mechanism of Action

The patient’s blood is progressively removed and replaced with donor blood or blood components. This can remove toxicants that are largely confined to the intravascular compartment and replace damaged blood cells. Possible Indications

Rarely considered for:  Severe methemoglobinemia refractory to standard therapy Selected severe poisoning in neonates or infants when other extracorporeal techniques are unsuitable Severe toxin-induced hemolysis in exceptional circumstances  Limitations / Complications  Transfusion reactions Hypothermia Hypotension Hypocalcemia Coagulopathy Thrombocytopenia Infection and other transfusion-related complications  Key Point

Exchange transfusion is now an uncommon, specialized rescue technique and is most useful when the relevant toxicant or toxic effect is concentrated within the blood.

Hemodialysis Mechanism of Action

Blood passes along a semipermeable membrane, allowing toxic substances to diffuse into the dialysate. A toxicant is generally easier to dialyze when it has:  Low molecular weight Low protein binding Small volume of distribution High water solubility  Modern high-flux dialysis can remove some substances that older dialysis systems handled poorly. Important Dialyzable Poisons

Hemodialysis has an established role in selected severe poisonings involving:  Methanol Ethylene glycol Lithium Salicylates Theophylline  It can also simultaneously correct:  Severe metabolic acidosis Electrolyte abnormalities Fluid disturbances  Dialysis may occasionally be used for other toxicants, but increased clearance alone does not mean that dialysis improves clinical outcomes enough to justify the procedure. Complications  Hypotension Fluid shifts Electrolyte abnormalities Vascular-access complications Bleeding related to anticoagulation  Important Considerations

Some antidotes, including fomepizole, can themselves be removed during dialysis, so antidote regimens may require adjustment under specialist guidance. After dialysis, the serum toxicant concentration may occasionally rebound because drug stored in tissues redistributes back into the bloodstream. Additional treatment may therefore be required. Key Point

Hemodialysis is most useful when the poison remains substantially in the bloodstream and can readily cross the dialysis membrane.

Hemoperfusion Mechanism of Action

Instead of relying primarily on diffusion across a membrane, hemoperfusion passes blood through a cartridge containing an adsorbent material, historically activated charcoal or resin. The toxicant binds to the cartridge and is removed from circulation. Potentially Suitable Toxicants

Hemoperfusion works best when a substance:  Has a relatively small volume of distribution Has low endogenous clearance Can be effectively adsorbed by the cartridge  Historically important examples include:  Theophylline Carbamazepine Phenobarbital  Limitations / Complications  Thrombocytopenia Bleeding and anticoagulation complications Vascular-access complications Hypotension Possible rebound after treatment  Unlike hemodialysis, hemoperfusion does not effectively correct metabolic acidosis, electrolyte abnormalities, or fluid disturbances. Current Role

Hemoperfusion is used much less frequently today because modern hemodialysis is more readily available and effective for many dialyzable poisonings. Key Points  CPB/VA-ECMO: supports circulation while the body clears the poison. Exchange transfusion: replaces circulating blood and is rarely used. Hemodialysis: removes small, water-soluble, relatively unbound toxicants and simultaneously corrects acid-base/electrolyte problems. Hemoperfusion: directly adsorbs circulating toxicants but has a more limited modern role. Decisions about extracorporeal treatment depend on the patient’s clinical severity as well as toxicant characteristics, rather than serum concentration alone. Early consultation with toxicology and nephrology/critical-care specialists is important when extracorporeal treatment may be required.

Toxicology – Nontoxic Ingestion

Definition

A nontoxic ingestion is an exposure to a substance that, at the estimated dose and route involved, is not expected to produce clinically significant toxicity.

The term should be used cautiously because even normally harmless substances can cause problems after unusually large exposures or aspiration.

When an Exposure Can Be Considered Nontoxic

Before classifying an ingestion as nontoxic, confirm that:

• The exact product has been reliably identified.
• Only one substance is involved.
• The product is in its original container and has not been replaced or contaminated.
• The approximate amount ingested is known.
• The route of exposure is known.
• The patient has no symptoms or abnormal examination findings.
• Reliable observation and follow-up are available.

If these conditions cannot be established, the exposure should generally be approached as an unknown ingestion.

Clinical Features

By definition, a true nontoxic ingestion should not produce significant systemic toxicity.

Very large exposures can still cause:

• Nausea or GI discomfort
• Vomiting or diarrhea
• Mechanical airway obstruction
• Aspiration-related lung injury

Development of unexpected symptoms should prompt reconsideration of the original history and possible exposure to another substance.

Common Low-Toxicity Household Exposures

Examples that are often minimally toxic after small accidental ingestions include:

• Crayons and chalk
• Graphite from pencils
• Ballpoint pen ink
• Many soaps and shampoos
• Shaving cream
• Petroleum jelly
• White glue
• Play dough
• Silica gel packets
• Small amounts of many cosmetics and lotions
• Water-based or latex paints

However, the specific formulation and amount still matter. Products within the same general category can contain different ingredients.

Medication Exposures

Some medications or topical products have relatively low toxicity after a small, isolated accidental exposure, but medication ingestions should still be assessed according to the specific drug and dose.

Examples historically considered relatively low risk in limited exposures include:

• Some antacids
• Calamine lotion
• Zinc oxide
• Many water-soluble vitamins

Importantly, iron-containing vitamins are an exception and can cause serious poisoning.

Plant Exposures

Many household plants cause little or no systemic toxicity, but plant identification can be unreliable and toxicity varies among species.

For a substantial or uncertain plant ingestion, accurate identification and consultation with a poison center are preferable to relying on a general “nontoxic plant” list.

Diagnosis

History is the most important part of the assessment. Determine:

• Exactly what substance was accessible
• How much may have been taken
• When the exposure occurred
• Whether other medications or chemicals were accessible
• Whether any symptoms occurred and subsequently resolved
• Whether the original container or packaging is available

If the history reliably establishes a truly nontoxic exposure and the patient remains asymptomatic, laboratory testing is generally unnecessary.

Management

For a confirmed nontoxic ingestion:

• Provide observation and supportive care as appropriate.
• Do not induce vomiting.
• Gastrointestinal decontamination is generally unnecessary.
• Confirm uncertain products or exposures with a poison center.

If symptoms develop or the substance, dose, or circumstances are uncertain, reassess the case as a potential toxic or unknown ingestion.

Key Points

• “Nontoxic” depends on the substance, dose, route, and certainty of the history.
• Accurate product identification is essential.
• An asymptomatic patient with a clearly identified low-risk exposure usually does not require extensive testing.
• Unexpected symptoms should trigger evaluation for an alternative or additional exposure.
• Even low-toxicity substances can cause problems through aspiration, airway obstruction, or massive ingestion.
• Avoid relying on old blanket lists of “nontoxic” products because modern formulations can vary.

Ophthalmology – X-Linked Retinoschisis

What the Disorder Represents

X-linked retinoschisis (XLRS) is an inherited vitreoretinal dystrophy caused by pathogenic variants in the RS1 gene.

It predominantly affects males and is characterized by:

• Bilateral foveal schisis
• Reduced central vision
• Peripheral retinoschisis in many patients
• Characteristic electroretinographic abnormalities
• Risk of vitreous hemorrhage and retinal detachment

The hallmark structural finding is:

Spoke-wheel cystic/schitic separation of the macula, usually without fluorescein leakage.

The Genetic Basis

XLRS is caused by pathogenic variants in:

RS1 on chromosome Xp22.13.

RS1 encodes:

Retinoschisin

a secreted retinal protein important for:

• Cellular adhesion
• Retinal structural organization
• Synaptic integrity

Loss of functional retinoschisin weakens adhesion between retinal cells and promotes:

Splitting within retinal layers.

Important Modern Correction About Pathogenesis

Older descriptions proposed that XLRS was primarily a:

• Müller-cell disorder
• Retinal vascular developmental disorder

Modern evidence instead indicates that the fundamental defect is:

Abnormal retinoschisin-mediated retinal cellular adhesion and signaling.

Müller cells and retinal neurons may participate secondarily, but they are not considered the sole primary cause.

Inheritance Pattern

XLRS is:

X-linked recessive.

It therefore affects almost exclusively:

Males.

Carrier females are usually asymptomatic because they possess a second normal X chromosome, although rare retinal abnormalities can occur with skewed X-inactivation or unusual genetic circumstances.

Family Transmission Pattern

For an affected male:

• All daughters inherit the pathogenic RS1 variant and are typically carriers
• Sons do not inherit the father’s X chromosome

For a carrier female, each pregnancy has approximately:

• 50% chance that a son will be affected
• 50% chance that a daughter will be a carrier

Genetic counseling is therefore important.

When Patients Usually Present

XLRS frequently becomes apparent during:

Childhood, often in the first decade.

Presentation may include:

• Reduced visual acuity
• Strabismus
• Reading difficulty
• Abnormal school vision screening

Severe disease may present in infancy with:

• Nystagmus
• Strabismus
• Vitreous hemorrhage
• Retinal detachment

Typical Visual Acuity

Central visual acuity is often moderately reduced rather than profoundly poor.

Many patients remain in the approximate range of:

20/40–20/100

for years, although severity is highly variable.

Marked early visual loss should raise concern for:

• Macular detachment
• Vitreous hemorrhage
• Retinal detachment
• Advanced macular degeneration

The Classic Macular Appearance

The hallmark fundus appearance is:

Foveal schisis with radial folds or cystic spaces forming a spoke-wheel pattern.

On ophthalmoscopy, the fovea may show:

• Fine radiating striae
• Microcystic appearance
• Reduced foveal reflex

This may be subtle clinically and is much easier to recognize with:

OCT.

Why It Is Called Retinoschisis

“Schisis” means:

Splitting.

In XLRS, the neurosensory retina separates within its retinal layers rather than separating completely from the RPE as occurs in ordinary retinal detachment.

Optical Coherence Tomography

OCT is the most useful structural test.

It typically demonstrates:

• Intraretinal schisis cavities
• Foveal thickening
• Radial cyst-like spaces
• Bridging retinal tissue

The cavities may involve several layers, particularly:

• Inner nuclear layer
• Outer plexiform layer
• Outer nuclear layer
• Occasionally other retinal layers

Important Modern Correction About the Retinal Layer

Older teaching often emphasized splitting primarily in the:

Nerve fiber layer.

Modern OCT demonstrates that macular schisis can involve:

Multiple retinal layers, with the inner nuclear layer being particularly common.

Why This Is Not Ordinary Cystoid Macular Edema

The OCT can resemble severe cystoid macular edema.

However, XLRS schisis represents:

Structural splitting rather than primarily vascular leakage.

This distinction is reflected on fluorescein angiography.

Fluorescein Angiography

One of the most useful diagnostic clues is:

Little or no fluorescein leakage from the foveal cystic spaces.

This helps distinguish XLRS from true cystoid macular edema due to:

• Uveitis
• Diabetes
• Retinal vein occlusion
• Postoperative inflammation

Thus:

Cystic OCT spaces + little FA leakage in a young male = consider XLRS.

Peripheral Retinoschisis

Peripheral schisis develops in approximately:

Half of affected patients, although reported frequencies vary.

It most commonly involves the:

Inferotemporal retina.

It may appear as:

• Elevated transparent retina
• Bullous schisis
• Inner retinal holes
• Abnormal retinal vessels crossing the schisis cavity

Vascular Changes

Retinal vessels traversing the schisis may be:

• Poorly supported
• Sheathed
• Tortuous

Occasionally there may be:

• Peripheral ischemia
• Telangiectatic change
• Neovascularization

Fragile unsupported vessels contribute to the risk of:

Vitreous hemorrhage.

Vitreous Veils

A classic peripheral finding is:

Vitreous veils

consisting of thin residual inner retinal tissue associated with peripheral schisis.

These may accompany:

• Inner-layer breaks
• Abnormal vessels

and can be diagnostically helpful.

Electroretinography

Full-field ERG classically demonstrates an:

Electronegative response

in which the:

• a-wave is relatively preserved
• b-wave is disproportionately reduced

This reflects dysfunction of transmission between photoreceptors and inner retinal bipolar pathways.

Important Modern Correction About ERG

An electronegative ERG is:

Characteristic but not universal.

Not every patient has the classic pattern, particularly:

• Very young patients
• Mild phenotypes
• Advanced retinal degeneration

Therefore a normal or atypical ERG does:

Not completely exclude XLRS.

Why the a-Wave and b-Wave Differ

The a-wave primarily reflects:

Photoreceptor activity.

The b-wave depends more heavily on:

• Bipolar cells
• Müller-cell-associated inner retinal activity

XLRS disproportionately disrupts inner retinal signaling, producing:

A low b-wave relative to the a-wave.

Genetic Testing

Molecular testing for:

RS1 pathogenic variants

is now a central part of diagnosis.

It can:

• Confirm XLRS
• Distinguish it from phenocopies
• Identify carrier females
• Support family counseling
• Determine eligibility for clinical trials

When Genetic Testing Is Particularly Useful

Consider testing in a male with:

• Bilateral foveal schisis
• Electronegative ERG
• Family history of similar disease
• Peripheral schisis

It is also valuable in atypical cases where:

OCT findings alone are not definitive.

Fundus Autofluorescence

FAF may show:

• Altered macular autofluorescence
• Changes corresponding to chronic RPE stress or atrophy

It is supportive but less important diagnostically than:

• OCT
• ERG
• Genetic testing

Visual Fields

Visual field testing may demonstrate:

• Central or paracentral sensitivity loss
• Scotomas corresponding to peripheral schisis
• Field loss from retinal detachment

It is not usually necessary for diagnosis in young children.

How the Disease Changes With Age

During childhood and early adulthood:

• Foveal schisis may remain stable or fluctuate

With increasing age:

• Schisis cavities may partially collapse
• Macular thinning develops
• RPE changes increase
• Outer retinal atrophy may become more prominent

Thus an older patient with genetically confirmed XLRS may have:

Macular atrophy with relatively little visible schisis.

Why Vision Can Worsen Later in Life

Late visual decline is often due not to increasing schisis but to:

• Macular atrophy
• Photoreceptor degeneration
• RPE abnormalities
• Prior retinal detachment
• Recurrent vitreous hemorrhage

Strabismus and Amblyopia

Children may develop:

• Strabismus
• Anisometropia
• Amblyopia

These treatable causes of additional visual loss should not be overlooked simply because an inherited retinal disorder is present.

Refractive Error

Hyperopia has traditionally been described in XLRS, but refractive error is variable.

Patients should receive:

Full appropriate optical correction

to maximize visual development.

Important Diagnostic Alternatives

The differential includes:

• Enhanced S-cone syndrome / Goldmann-Favre phenotype
• Acquired degenerative retinoschisis
• Cystoid macular edema
• Familial exudative vitreoretinopathy
• Retinitis pigmentosa
• Retinal vasculitis
• Wagner syndrome
• Other inherited vitreoretinopathies

XLRS vs Acquired Degenerative Retinoschisis

XLRS

• Young male
• Bilateral
• Foveal schisis characteristic
• RS1 mutation
• Electronegative ERG may occur

Degenerative Retinoschisis

• Usually older adults
• Peripheral retinal splitting
• Typically no characteristic foveal schisis
• Not X-linked

XLRS vs Enhanced S-Cone Syndrome

Enhanced S-cone syndrome may also cause:

• Foveal schisis
• Peripheral retinal degeneration

However, patients commonly have:

• Prominent nyctalopia
• Characteristic pigmentary changes
• Distinctive ERG abnormalities involving enhanced S-cone function
• Autosomal recessive NR2E3 disease

XLRS vs True Cystoid Macular Edema

True CME generally shows:

Fluorescein leakage.

XLRS macular cavities typically show:

Minimal or absent leakage.

This is a classic examination distinction.

The Main Treatment Principle

There is currently:

No approved curative or disease-modifying treatment for XLRS.

Management focuses on:

• Maximizing useful vision
• Treating refractive error and amblyopia
• Reducing schisis in selected patients
• Detecting retinal complications early

Carbonic Anhydrase Inhibitors

Topical:

Dorzolamide

or systemic:

Acetazolamide

may reduce macular schisis cavities in some patients.

The response is variable.

What CAIs Can Achieve

Some patients demonstrate:

• Decreased central retinal thickness
• Smaller schisis cavities
• Modest improvement in visual acuity

Others show:

• Structural improvement without meaningful visual change
• No response
• Recurrence despite continued therapy

Therefore treatment should be assessed using:

Both OCT and visual function.

Why CAIs May Help

The exact mechanism is uncertain but may involve effects on:

• RPE ion transport
• Retinal fluid movement

The treatment does not correct the underlying:

RS1 genetic defect.

Topical vs Oral CAI

Topical dorzolamide is often tried first because systemic therapy has more adverse effects.

Oral acetazolamide may produce:

• Paresthesias
• Fatigue
• Electrolyte disturbances
• Nephrolithiasis
• Metabolic acidosis

Long-term treatment therefore requires appropriate monitoring.

Prophylactic Laser Is Not Recommended

Laser photocoagulation around uncomplicated peripheral schisis has historically been attempted.

Routine prophylactic laser is:

Not recommended.

It can:

• Create retinal breaks
• Increase traction
• Potentially precipitate rhegmatogenous retinal detachment

Observation is preferred unless there is a specific treatable complication.

Vitreous Hemorrhage

Vitreous hemorrhage may result from:

• Rupture of unsupported vessels
• Traction
• Less commonly retinal neovascularization

Many hemorrhages clear spontaneously.

When Vitrectomy Is Needed for Hemorrhage

Pars plana vitrectomy may be considered when hemorrhage is:

• Dense
• Recurrent
• Nonclearing
• Preventing evaluation of the retina

Earlier intervention may be considered in young children because prolonged visual deprivation can cause:

Amblyopia.

Retinal Detachment

Retinal detachment is one of the most important complications.

Mechanisms include:

• Outer retinal breaks
• Inner and outer layer breaks
• Vitreoretinal traction
• Combination of schisis and rhegmatogenous detachment

Why Retinal Detachment Is Technically Difficult

XLRS eyes may have:

• Fragile retina
• Abnormal vitreoretinal adhesion
• Large schisis cavities
• Thin inner retinal layers

These features complicate retinal repair.

Surgical Management of Retinal Detachment

Modern repair commonly uses:

Pars plana vitrectomy with internal tamponade

when significant traction or complex retinal breaks are present.

Additional options may include:

• Laser retinopexy around true breaks
• Gas or silicone oil tamponade
• Scleral buckle in selected configurations

Surgical planning should be individualized by a vitreoretinal surgeon.

Why Not Every Schisis Cavity Needs Surgery

A stable peripheral schisis cavity without:

• Progressive retinal detachment
• Vision-threatening extension
• Significant traction

usually requires:

Observation rather than intervention.

Operating on structurally fragile retina can create more harm than benefit.

Retinal Neovascularization

True neovascularization is uncommon but may occur with peripheral ischemia.

Management may include:

• Laser photocoagulation to ischemic retina
• Anti-VEGF as an adjunct in selected cases

Treatment is directed at the complication rather than the underlying XLRS.

Role of Gene Therapy

Because XLRS results from loss of a secreted retinal protein, it has been an attractive target for:

RS1 gene-replacement therapy.

Human clinical trials using intravitreal gene therapy have demonstrated:

• Biological activity
• Significant inflammatory challenges
• Variable structural and functional benefit

As of current clinical practice:

No RS1 gene therapy is approved for routine treatment.

Why Gene Therapy Remains Challenging

Effective treatment must deliver functional RS1 broadly across the retina while avoiding:

• Intraocular inflammation
• Immune responses to viral vectors
• Retinal toxicity

Research continues.

Low-Vision Support

Patients with significant central visual impairment may benefit from:

• Magnification
• Electronic reading aids
• Classroom accommodations
• High-contrast materials
• Low-vision rehabilitation

Children should receive appropriate educational support early.

Activity and Eye Protection

There is no universal evidence-based prohibition against ordinary physical activity.

However, because vitreous hemorrhage and retinal detachment can occur:

• Significant ocular trauma should be avoided
• Protective eyewear is reasonable during high-risk activities

Restrictions should be individualized rather than imposing blanket sports bans.

Follow-Up Strategy

Patients require regular lifelong retinal follow-up.

Monitor:

• Visual acuity
• Refraction
• Strabismus/amblyopia
• Macular OCT
• Peripheral retina
• Vitreous hemorrhage
• Retinal detachment

The interval depends on:

• Age
• Severity
• Peripheral schisis
• Previous complications

Symptoms Requiring Urgent Reassessment

Patients and families should seek prompt retinal evaluation for:

• Sudden increase in floaters
• Photopsias
• Curtain or field defect
• Sudden reduction in vision

These can indicate:

• Vitreous hemorrhage
• Retinal tear
• Retinal detachment

Expected Long-Term Course

XLRS usually progresses:

Slowly.

Many patients retain useful central vision through childhood and early adulthood.

Later deterioration can occur from:

• Macular atrophy
• Retinal detachment
• Recurrent hemorrhage
• Outer retinal degeneration

The course varies considerably even among members of the same family.

Major Causes of Permanent Visual Loss

These include:

• Macular atrophy
• Retinal detachment
• Recurrent vitreous hemorrhage
• Amblyopia
• Advanced outer retinal degeneration

The schisis cavities themselves do not always correlate directly with visual acuity.

High-Yield Takeaways

• X-linked retinoschisis is an X-linked recessive inherited retinal dystrophy caused by pathogenic variants in RS1, which encodes retinoschisin.
• It affects almost exclusively males, usually presenting during childhood with reduced central vision.
• The hallmark is bilateral foveal schisis with a spoke-wheel appearance.
• Peripheral schisis occurs in roughly half of patients, classically inferotemporally.
• Modern OCT shows schisis involving multiple retinal layers, particularly the inner nuclear layer; it is not confined to the nerve fiber layer.
• The macular cavities resemble CME on OCT but typically show little or no fluorescein leakage.
• A classic ERG demonstrates an electronegative response with disproportionately reduced b-wave, but this is not present in every patient.
• RS1 genetic testing is now a central diagnostic tool and enables carrier testing and genetic counseling.
• Older patients may show macular atrophy with collapse of previously obvious schisis cavities.
• Treat refractive error, strabismus, and amblyopia aggressively because these can add preventable visual loss.
• Topical dorzolamide or oral acetazolamide may reduce macular schisis in selected patients, although visual benefit is variable.
• Routine prophylactic laser around peripheral schisis is not recommended because it may increase retinal complications.
• Vitreous hemorrhage often clears spontaneously, but persistent or dense hemorrhage may require vitrectomy, especially during the amblyogenic years.
• Retinal detachment may result from retinal breaks and vitreoretinal traction and frequently requires pars plana vitrectomy with individualized tamponade.
• True retinal neovascularization is uncommon; when present, treatment targets the ischemic complication rather than the inherited schisis itself.
• No approved curative or RS1 gene-replacement therapy currently exists, although gene therapy remains under investigation.
• Sudden floaters, photopsias, field loss, or abrupt visual decline require urgent examination for vitreous hemorrhage or retinal detachment.
• The disease is usually slowly progressive, with late visual decline often resulting from macular atrophy rather than simply enlargement of the schisis cavities.
• Lifelong retinal surveillance and genetic counseling are essential.

High-Yield Takeaways

Ophthalmology – Wyburn–Mason Syndrome

What the Disorder Represents

Wyburn–Mason syndrome is a rare congenital, usually sporadic neuro-oculo-cutaneous vascular malformation syndrome characterized by arteriovenous malformations (AVMs) involving the retina and, in many affected patients, the ipsilateral brain, orbit, or facial structures.

It is also called:

• Bonnet–Dechaume–Blanc syndrome
• Retinocephalic vascular malformation syndrome
• Racemose hemangiomatosis

The characteristic ocular lesion is a:

Retinal arteriovenous malformation with direct communication between arteries and veins.

An Important Modern Distinction

An isolated retinal AVM is not automatically equivalent to Wyburn–Mason syndrome.

The term Wyburn–Mason syndrome is most appropriately used when retinal AVMs occur as part of a broader ipsilateral vascular malformation involving structures such as:

• Brain
• Orbit
• Face
• Maxillofacial tissues

A patient with a retinal racemose AVM should therefore be evaluated for:

Associated intracranial and orbital vascular malformations.

How the Vascular Malformation Develops

AVMs arise from abnormal embryologic vascular development.

Instead of normal progression:

Artery → arteriole → capillary bed → venule → vein

there is an abnormal direct connection between:

Arterial and venous circulations.

This creates a high-flow vascular shunt.

Why the Vessels Become So Dilated

Without the resistance of a normal capillary bed:

• Arterial blood enters veins at high pressure
• Feeding arteries enlarge
• Draining veins become dilated and tortuous
• High-flow shunting may develop

The retinal lesion therefore often looks like:

A striking tangle of enormously dilated arteries and veins with direct arteriovenous communication.

Genetic Pattern

Wyburn–Mason syndrome is generally:

Sporadic and nonhereditary.

No consistent Mendelian inheritance pattern has been established.

Routine family screening is therefore usually unnecessary unless another inherited vascular disorder is suspected.

Typical Laterality

The disorder is usually:

Unilateral

and associated CNS or facial vascular malformations tend to occur on the:

Same side as the retinal lesion.

Bilateral retinal involvement is unusual.

When It Becomes Apparent

The malformation is congenital, but diagnosis can occur at almost any age.

Some patients are detected:

• Incidentally during routine eye examination
• During evaluation for reduced vision
• After neurologic symptoms
• Following intracranial hemorrhage

Thus congenital disease does not necessarily mean:

Childhood presentation.

What Patients May Notice

Many patients with retinal AVMs remain asymptomatic.

Possible ocular symptoms include:

• Reduced visual acuity
• Visual-field loss
• Diplopia
• Eye redness
• Floaters
• Proptosis
• Ocular discomfort

Visual symptoms depend mainly on:

• Macular involvement
• Optic nerve involvement
• Vascular complications

Neurologic Symptoms

Associated intracranial AVMs may produce:

• Headache
• Seizures
• Focal weakness
• Sensory deficits
• Cranial nerve palsies
• Visual-field loss
• Altered consciousness

The most serious presentation is:

Intracranial hemorrhage.

Craniofacial Manifestations

Associated vascular malformations may involve:

• Orbit
• Conjunctiva
• Eyelids
• Face
• Maxilla
• Mandible
• Oral cavity

Possible findings include:

• Facial vascular lesions
• Dilated conjunctival vessels
• Epistaxis
• Oral bleeding
• Proptosis

Significant oral or maxillofacial AVMs can produce severe hemorrhage after:

Dental extraction or surgery.

The Classic Retinal Appearance

Fundus examination may show:

• Markedly dilated retinal arteries
• Markedly dilated retinal veins
• Tortuous vessels
• Direct artery-to-vein communications
• Little or no intervening normal capillary network

The vessels may involve:

• A limited retinal sector
• An entire retinal quadrant
• Much of the retina
• Optic nerve head

Traditional Retinal AVM Classification

The classic Archer classification divides retinal AVMs into three groups.

Group 1 – Mild AV Communication

There is an abnormal vascular network between artery and vein with a relatively recognizable intervening capillary component.

These lesions are generally:

• Less extensive
• Less visually destructive
• Less strongly associated with CNS AVMs

They may sometimes represent an isolated retinal vascular malformation rather than full Wyburn–Mason syndrome.

Group 2 – Direct Arteriovenous Communication

There is:

Direct communication between a retinal artery and vein without a normal intervening capillary bed.

The involved vessels are:

• Enlarged
• Tortuous
• High-flow

This pattern has a stronger association with:

Ipsilateral intracranial AVMs.

Group 3 – Extensive Racemose Malformation

This is the most dramatic phenotype.

Features include:

• Massive dilation of arteries and veins
• Numerous direct AV communications
• Extensive retinal involvement
• Difficulty distinguishing artery from vein

These eyes carry the greatest risk of:

• Poor vision
• Vascular occlusion
• Glaucoma
• Optic nerve damage

They are also more strongly associated with:

CNS involvement.

Optic Nerve Involvement

AVMs may involve or surround the optic disc.

Possible consequences include:

• Optic disc edema
• Optic atrophy
• Reduced color vision
• RAPD when asymmetric
• Visual-field loss

Vision may be limited from birth or deteriorate later because of vascular complications.

Why Vision May Be Poor Even Without Hemorrhage

Reduced vision can result from:

• Macular involvement by anomalous vessels
• Chronic retinal ischemia
• Optic nerve dysfunction
• Amblyopia in childhood
• Vascular occlusion
• Secondary glaucoma

Therefore visual loss is not necessarily due to bleeding.

Fluorescein Angiography

FA classically demonstrates:

Very rapid arteriovenous transit through the abnormal communications.

Typical findings include:

• Early arterial filling
• Almost immediate filling of draining veins
• Enlarged feeding and draining vessels

Unlike retinal neovascularization, uncomplicated AVMs generally show:

Little or no leakage.

Why the Lack of Leakage Matters

The absence of substantial fluorescein leakage helps distinguish congenital AVMs from:

• Proliferative diabetic retinopathy
• Retinal neovascularization
• Vasoproliferative tumors

Leakage may occur if secondary vascular complications develop.

Optical Coherence Tomography

OCT can demonstrate:

• Enlarged intraretinal vascular channels
• Shadowing beneath abnormal vessels
• Distortion of retinal layers
• Macular edema if complications develop

OCT is most useful when the AVM approaches:

The macula or optic nerve.

OCT Angiography

OCTA can noninvasively demonstrate:

• Abnormal high-flow retinal vessels
• Direct arteriovenous channels
• Distortion of superficial and deep vascular plexuses

It is useful for structural vascular mapping but does not replace angiographic or neurovascular imaging when associated cerebral AVMs are suspected.

Why Brain Imaging Is Essential

A patient with a retinal AVM suggestive of Wyburn–Mason syndrome should undergo evaluation for:

Intracranial and orbital AVMs.

Initial imaging usually includes:

• MRI of the brain and orbits
• MRA

CTA may be used in selected circumstances.

Role of Catheter Cerebral Angiography

Digital subtraction angiography provides the most detailed assessment of:

• Feeding arteries
• Nidus architecture
• Venous drainage
• High-risk aneurysms

It is not required for every incidental retinal AVM.

It is generally reserved when:

• MRI/MRA identifies an intracranial AVM
• Treatment is being considered
• Detailed neurovascular anatomy is required

Why Neurology or Neurosurgery Referral Matters

Retinal AVMs can be the first visible sign of a clinically silent:

Cerebral AVM.

Identification of a retinal racemose malformation therefore warrants neurovascular evaluation even when the patient has:

No neurologic symptoms.

Important Ocular Complications

Although many retinal AVMs remain stable, complications can include:

• Retinal vein occlusion
• Retinal ischemia
• Macular edema
• Retinal hemorrhage
• Vitreous hemorrhage
• Secondary neovascularization
• Secondary glaucoma
• Optic neuropathy

Retinal Vascular Occlusion

Abnormal hemodynamics may predispose to:

• Branch retinal vein occlusion
• Central retinal vein occlusion
• Less commonly arterial compromise

Occlusion may produce:

• Retinal hemorrhage
• Macular edema
• Ischemia
• Neovascularization

Neovascular Glaucoma

Extensive retinal ischemia after vascular occlusion may produce:

VEGF-driven iris and angle neovascularization.

This may lead to:

Neovascular glaucoma.

Treatment requires management of both:

• Retinal ischemia
• Elevated IOP

Glaucoma From Elevated Episcleral Venous Pressure

A second glaucoma mechanism can occur when orbital or episcleral AV communications raise:

Episcleral venous pressure.

Clinical clues include:

• Dilated episcleral vessels
• Elevated IOP
• Open angle
• Blood in Schlemm canal on gonioscopy in some cases

This mechanism differs from neovascular glaucoma.

Why the Glaucoma Mechanism Must Be Identified

Management differs substantially between:

Ischemic neovascular glaucoma

Requires suppression of retinal VEGF drive.

Elevated episcleral venous pressure

Results from impaired aqueous drainage against an abnormally high venous pressure.

Gonioscopy and retinal examination are therefore essential.

Treating Elevated IOP

Medical treatment may include:

• Topical beta-blocker
• Carbonic anhydrase inhibitor
• Alpha-2 agonist
• Prostaglandin analogue

Systemic acetazolamide may be used when stronger short-term IOP lowering is needed.

Role of Miotics

Older references listed miotics among routine glaucoma therapies.

They are not particularly useful for the typical mechanisms of glaucoma in Wyburn–Mason syndrome and are:

Not a preferred modern first-line strategy.

Treatment should be based on the actual glaucoma mechanism.

Treating Neovascular Complications

When retinal ischemia produces neovascularization:

• Panretinal photocoagulation (PRP) may be indicated
• Intravitreal anti-VEGF can provide rapid temporary regression of neovascularization

Anti-VEGF is an adjunct because:

The underlying ischemic retina remains the definitive treatment target.

Important Correction About Laser Treatment

The congenital retinal AVM itself is generally:

Not treated with destructive laser simply because it is present.

Direct photocoagulation of a high-flow retinal AVM can be hazardous and is rarely appropriate.

Laser is primarily directed at:

Secondary ischemic or neovascular complications.

Vitreous Hemorrhage

Nonclearing vitreous hemorrhage may require:

Pars plana vitrectomy

especially if:

• Vision remains substantially reduced
• Retinal traction is present
• Retinal pathology cannot otherwise be monitored

Amblyopia

Children with unilateral visual impairment may develop:

Amblyopia.

When appropriate, management may include:

• Optical correction
• Patching
• Atropine penalization in selected cases

However, amblyopia treatment can only improve the portion of vision loss attributable to abnormal visual development, not structural retinal damage.

Strabismus

Strabismus may occur from:

• Poor unilateral vision
• Cranial nerve dysfunction
• Orbital involvement

Management depends on:

• Visual potential
• Stability
• Neurologic status

Surgery can be considered when appropriate.

Management of the Retinal AVM Itself

For an uncomplicated retinal AVM:

Observation is usually the preferred strategy.

Follow with:

• Visual acuity
• IOP
• Dilated fundus examination
• Photography
• OCT when useful

Treatment is reserved for:

Complications rather than the vascular anomaly itself.

Does the AVM Spontaneously Disappear?

True spontaneous involution is:

Uncommon and should not be expected.

Most congenital retinal AVMs are structurally persistent, although their appearance and complications may remain stable for long periods.

Treatment of Intracranial AVMs

Management of a cerebral AVM is highly individualized.

Options can include:

• Observation
• Endovascular embolization
• Microsurgical resection
• Stereotactic radiosurgery
• Multimodal treatment

The decision depends on:

• AVM size
• Location
• Venous drainage
• Previous hemorrhage
• Neurologic symptoms
• Treatment risk

Why Not Every Brain AVM Is Treated

Intervention itself can cause:

• Stroke
• Hemorrhage
• Neurologic deficit
• Death

Therefore neurosurgical management requires careful comparison of:

Natural-history risk vs treatment risk.

Retinal AVM presence alone is not an automatic indication for brain AVM intervention.

Oral and Maxillofacial Precautions

If facial, mandibular, or oral AVMs are present, apparently routine procedures such as:

• Dental extraction
• Biopsy
• Oral surgery

can provoke:

Severe hemorrhage.

Relevant vascular imaging should precede invasive procedures when a significant maxillofacial AVM is suspected.

Key Diagnostic Alternatives

Important differentials include:

• Congenital retinal macrovessel
• Retinal cavernous hemangioma
• Retinal capillary hemangioblastoma
• Vasoproliferative retinal tumor
• Retinal telangiectasia
• Retinal collaterals
• Intraretinal microvascular abnormalities
• Sturge-Weber syndrome

Wyburn–Mason vs Von Hippel-Lindau Disease

Wyburn–Mason

• Direct retinal artery-vein communications
• Markedly dilated racemose vessels
• Usually unilateral
• Associated with CNS AVMs
• No discrete vascular tumor required

VHL

• Retinal capillary hemangioblastoma
• Orange-red tumor mass
• Prominent feeding arteriole and draining venule
• Often multiple/bilateral
• Associated with RCC, CNS hemangioblastoma, pheochromocytoma, etc.

Wyburn–Mason vs Retinal Cavernous Hemangioma

Retinal cavernous hemangioma consists of:

• Clusters of thin-walled venous aneurysms
• “Bunch of grapes” appearance
• Slow blood flow
• Plasma-erythrocyte layering

This is very different from the:

High-flow artery-to-vein shunting of Wyburn–Mason syndrome.

Wyburn–Mason vs Sturge-Weber Syndrome

Sturge-Weber syndrome classically involves:

• Port-wine birthmark
• Leptomeningeal capillary-venous malformation
• Diffuse choroidal hemangioma
• Glaucoma

Wyburn–Mason instead features:

True high-flow arteriovenous malformations of the retina and CNS.

Wyburn–Mason vs Congenital Retinal Macrovessel

A congenital retinal macrovessel is usually:

• A single anomalous large retinal vessel
• Often crossing the horizontal raphe
• Frequently incidental

It does not usually produce the extensive direct arteriovenous shunting seen in:

Racemose retinal AVMs.

Long-Term Monitoring

Patients should receive periodic:

Ophthalmic surveillance

for:

• Vision
• IOP
• Retinal vascular complications
• New hemorrhage
• Neovascularization

Neurologic follow-up depends on the presence and anatomy of associated CNS disease.

When Urgent Assessment Is Needed

Patients require urgent evaluation for:

• Sudden severe headache
• New neurologic deficit
• Seizure
• Altered consciousness
• Sudden visual loss
• Painful red eye with elevated IOP
• Vitreous hemorrhage

These may represent:

• Intracranial hemorrhage
• Retinal vascular occlusion
• Neovascular glaucoma
• Other acute complications

Expected Ocular Course

Prognosis varies greatly.

A limited peripheral retinal AVM may remain stable with excellent vision.

More extensive lesions involving:

• Macula
• Optic nerve
• Major retinal circulation

can cause significant permanent visual impairment.

What Determines Neurologic Prognosis

Systemic prognosis depends principally on:

• Location and size of cerebral AVMs
• Previous intracranial hemorrhage
• Associated aneurysms
• Neurologic deficits
• Feasibility and risk of treatment

Some patients remain neurologically asymptomatic throughout life.

High-Yield Takeaways

• Wyburn–Mason syndrome is a rare, usually sporadic congenital disorder characterized by retinal AVMs associated with ipsilateral cerebral, orbital, or craniofacial AVMs.
• It is also called Bonnet–Dechaume–Blanc syndrome or retinocephalic vascular malformation syndrome.
• An isolated retinal AVM does not automatically establish Wyburn–Mason syndrome; associated CNS disease should be sought.
• Retinal AVMs consist of direct artery-to-vein communications with absent or reduced intervening capillary beds.
• The classic fundus appearance is massively dilated, tortuous arteries and veins with direct arteriovenous shunting.
• The traditional Archer classification includes Group 1 mild AV communication, Group 2 direct AV communication, and Group 3 extensive racemose malformation.
• More extensive Group 2 and 3 lesions have a stronger association with intracranial AVMs.
• FA classically shows rapid arteriovenous transit with little leakage in uncomplicated lesions.
• OCT and OCTA can document retinal structural distortion and abnormal vascular channels.
• Discovery of a significant retinal AVM should prompt brain/orbital MRI and vascular imaging, usually MRI/MRA initially.
• Catheter cerebral angiography is reserved for selected patients when an intracranial AVM requires detailed characterization or treatment planning.
• The retinal AVM itself is usually observed rather than directly treated.
• Important ocular complications include retinal vein occlusion, retinal ischemia, vitreous hemorrhage, macular edema, neovascularization, and glaucoma.
• Glaucoma may arise from either retinal ischemia causing neovascular glaucoma or elevated episcleral venous pressure from orbital AV shunting.
• PRP and anti-VEGF are used for secondary ischemic neovascular complications, not routinely to eradicate the congenital AVM.
• Vitrectomy may be required for nonclearing vitreous hemorrhage or tractional complications.
• Severe oral or maxillofacial AVMs may produce dangerous hemorrhage during dental or surgical procedures.
• Cerebral AVM management may involve observation, embolization, microsurgery, stereotactic radiosurgery, or combinations, depending on individualized hemorrhage and treatment risk.
• Wyburn–Mason is distinct from VHL, which produces retinal capillary hemangioblastomas, and from Sturge-Weber, which produces capillary-venous malformations and diffuse choroidal hemangioma.
• Patients require long-term ophthalmic and neurologic surveillance because complications can develop despite years of stability.

High-Yield Takeaways